In recent clinical investigations, Eli Lilly's innovative GLP-1 tablet, Foundayo, showed positive outcomes in mitigating the severity of sleep apnea. However, the data suggested that its impact might not be as robust as that of Zepbound, the company's injectable counterpart.
During a year-long study involving participants who were not undergoing positive airway pressure (PAP) therapy, Foundayo exhibited a reduction of 17.8 events per hour on the apnea-hypopnea index (AHI). This index quantifies instances where breathing ceases or is restricted during sleep. In contrast, the placebo group experienced a reduction of only 4.5 events. Furthermore, 28% of patients receiving Foundayo achieved either remission or a mild form of the disease, a notable improvement compared to 13% in the placebo cohort. These findings were presented at the American Heart Association's annual meeting and subsequently published in JAMA.
This research highlights the potential of Foundayo as a valuable addition to sleep apnea treatments, particularly for patients who may not be candidates for or prefer alternatives to PAP therapy. The successful reduction in AHI events and the achievement of disease remission or milder states indicate a significant step forward in managing this condition. While Zepbound remains a highly effective treatment, Foundayo offers a convenient oral option that could broaden access to care and improve patient adherence.
The successful development of Foundayo underscores the continuous advancements in pharmaceutical research aimed at improving patient health and well-being. Eli Lilly's commitment to exploring diverse therapeutic avenues provides hope for individuals suffering from chronic conditions like sleep apnea, ultimately contributing to a healthier society by offering more accessible and varied treatment choices.
